暫無數據
代碼股票名稱
最新價漲跌額漲跌幅成交量成交額今開昨收最高最低總市值流通市值總股本流通股本5日漲跌幅10日漲跌幅20日漲跌幅60日漲跌幅120日漲跌幅250日漲跌幅年初至今漲跌幅股息率TTM換手率市盈率TTM市盈率(靜)振幅所屬行業
美股期權個股詳情
BTAI240517C1000
- 0.85
- 0.000.00%
延時15分鐘行情交易中 05/17 15:58 (美東)
0.00最高價0.00最低價
0.00今開0.85昨收0張成交量0張未平倉合約數1.00行權價0.00成交額0.00%引伸波幅-10.63%溢價2024/05/17到期日1.07内在价值100合約乘數-2天距到期日0.00時間價值100合約規模美式期權類型--Delta--Gamma2.44槓桿倍數--Theta--Rho--有效槓桿--Vega
分時
- 5日
- 日K
暫無內容
新聞
在增長潛力和財務不確定性下，維持對Bioxcel Therapeutics的評級
BioXcel Therapeutics, Inc.（納斯達克股票代碼：BTAI）2024年第一季度業績電話會議記錄
看漲前景：Bioxcel Therapeutics的收入激增和前景樂觀的臨床試驗推動了買入評級
2024年第一季度BioXcel Therapeutics Inc業績電話會議
快訊 | BioXcel Therapeutics公佈的第一季度財務業績好於預期後，該公司股價走高
BioXcel Therapeutics, Inc. (BTAI) 2024 年第一季度業績電話會議記錄
BioXcel Therapeutics, Inc. (BTAI) 2024 年第一季度業績電話會議記錄
評論
$BioXcel Therapeutics(BTAI.US$BioXcel Therapeutics Q1 2024 GAAP EPS $(0.87) Beats $(1.04) Estimate, Sales $582.000K Beat $464.000K Estimate
1
$BioXcel Therapeutics(BTAI.US$
NEWS
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
The late-breaking abstract on preliminary findings from the Phase 2 trial of BXCL701 and KEYTRUDA® in metastatic pancreatic ductal adenocarcinoma has been selected for presentation at the 2024 ASCO Annual Meeti...
NEWS
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
The late-breaking abstract on preliminary findings from the Phase 2 trial of BXCL701 and KEYTRUDA® in metastatic pancreatic ductal adenocarcinoma has been selected for presentation at the 2024 ASCO Annual Meeti...
2
$BioXcel Therapeutics(BTAI.US$ BioXcel Therapeutics Announced Details Regarding The Planned Design Of Its Upcoming TRANQUILITY In-care Phase 3 Trial Of BXCL501 For Agitation Associated With Alzheimer's Dementia
1
$BioXcel Therapeutics(BTAI.US$ BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
13 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
13 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
1
1
閱讀更多